{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:44:05Z","timestamp":1785897845574,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009873","name":"Autonomous Region of Sardinia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pnpbp.2025.111292","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T02:26:23Z","timestamp":1739759183000},"page":"111292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder"],"prefix":"10.1016","volume":"137","author":[{"given":"Alessio","family":"Squassina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Paribello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Contu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pisanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Congiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Severino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Conversano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Zompo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Bernoni","family":"d'Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gennarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Carpiniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Manchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2025.111292_bb0005","series-title":"Diagnostic And Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pnpbp.2025.111292_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104965","article-title":"Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: systematic review and meta-analysis of randomised controlled trials","volume":"144","author":"Arnone","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111292_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ph17111461","article-title":"CYP2C19 genetic variants and major depressive disorder: a systematic review","volume":"17","author":"Bonasser","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111292_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1288-1061","article-title":"Review and consensus on pharmacogenomic testing in psychiatry","volume":"54","author":"Bousman","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111292_bb0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: a rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111292_bb0045","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111292_bb0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40261-022-01182-2","article-title":"Cost-utility analysis of pharmacogenetic testing based on CYP2C19 or CYP2D6 in major depressive disorder: assessing the drivers of different cost-effectiveness levels from an Italian societal perspective","volume":"42","author":"Carta","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0055","series-title":"CPIC\u00ae guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19","author":"CPIC","year":"2019"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111292_bb0060","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.698148","article-title":"An analysis of pharmacogenomic-guided pathways and their effect on medication changes and hospital admissions: a systematic review and meta-analysis","volume":"12","author":"David","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0070","series-title":"Structured Clinical Interview for the DSM (SCID)","author":"First","year":"2015"},{"issue":"44","key":"10.1016\/j.pnpbp.2025.111292_bb0075","doi-asserted-by":"crossref","first-page":"E1499","DOI":"10.1503\/cmaj.221785","article-title":"Cost-effectiveness of pharmacogenomic-guided treatment for major depression","volume":"195","author":"Ghanbarian","year":"2023","journal-title":"CMAJ"},{"key":"10.1016\/j.pnpbp.2025.111292_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111292_bb0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br. J. Soc. Clin. Psychol."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2024.05.003","article-title":"Meta-analyses of pharmacogenetics-guided antidepressant treatment: reply to milosavljevic","volume":"85","author":"Heilbronner","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"17","key":"10.1016\/j.pnpbp.2025.111292_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231710058","article-title":"Genetic variation among Pharmacogenes in the Sardinian population","volume":"23","author":"Idda","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111292_bb0100","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2022.10018","article-title":"Pharmacogenomic testing for next-step antidepressant selection: still a work in progress","volume":"328","author":"Iosifescu","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111292_bb0105","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Pharmacogenomics in treatment of depression and psychosis: an update","volume":"43","author":"Jukic","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111292_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.2022.23","article-title":"The potential of precision psychiatry: what is in reach?","volume":"220","author":"Kambeitz-Ilankovic","year":"2022","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111292_bb0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0706743720904820","article-title":"Pharmacogenetic testing options relevant to psychiatry in Canada: options de tests pharmacogenetiques pertinents en psychiatrie au Canada","volume":"65","author":"Maruf","year":"2020","journal-title":"Can. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111292_bb0125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevic","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111292_bb0135","first-page":"89","article-title":"Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review","volume":"22","author":"O'Shea","year":"2022","journal-title":"Pharm. J."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111292_bb0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovic","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0150","author":"PharmGKB Database"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111292_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.pnpbp.2025.111292_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jad.2020.04.058","article-title":"Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder","volume":"273","author":"Ren","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"15","key":"10.1016\/j.pnpbp.2025.111292_bb0165","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jpsychires.2010.03.006","article-title":"Response and remission criteria in major depression \u2013 a validation of current practice","volume":"44","author":"Riedel","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113649","article-title":"Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression","volume":"296","author":"Rothschild","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2025.111292_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105910","article-title":"Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints","volume":"89","author":"Rua\u00f1o","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.pnpbp.2025.111292_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113571","article-title":"Subanalysis of the CYP-GUIDES trial: CYP2D6 functional stratification and operational timeline selection","volume":"297","author":"Rua\u00f1o","year":"2021","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Control. Clin. Trials"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111292_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121334","article-title":"Serotonin transporter genetic variation and antidepressant response and tolerability: a systematic review and meta-analysis","volume":"11","author":"Stein","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111292_bb0200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41398-022-01963-5","article-title":"Correction: clinical utility of combinatorial pharmacogenomic testing in depression: a Canadian patient- and rater-blinded, randomized, controlled trial","volume":"12","author":"Tiwari","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111292_bb0205","first-page":"200","article-title":"Associations between the 1438A\/G, 102T\/C, and rs7997012G\/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis","volume":"21","author":"Wan","year":"2021","journal-title":"Pharm. J."}],"updated-by":[{"DOI":"10.1016\/j.pnpbp.2025.111453","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000}}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:41:32Z","timestamp":1758192092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S0278584625000466"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111292","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111292"}}